Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Clinical Trial With Ex Vivo Expanded Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

NCT03592706 is registered in ClinicalTrials.gov with Ivy Life Sciences, Co., Ltd as lead sponsor.

NCT NCT03592706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03592706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Clinical Trial With Ex Vivo Expanded Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
Lead sponsor
Ivy Life Sciences, Co., Ltd
Phase
Phase 2/3
Overall status
Unknown status
Start date
December 31, 2009
Completion date
August 31, 2021
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver cancer